Healthcare
Live Price
Offline$38.88
+1.43% today
1Y Change
+96.57%
Window
Jun 30, 2025 → Jun 22, 2026
Coverage: 245 bars · Jun 30, 2025 → Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Guardian Pharmacy Services, Inc. (GRDN) is a Healthcare stock with a market cap of $2.33B and listed on NYSE. The stock last traded around $38.88 and up 96.6% across the available one-year price window (Jun 30, 2025 → Jun 22, 2026). Baseline metrics include revenue growth of +17.9%, EPS growth of +144.6%, a dividend yield of 0.0%. What stands out right now is revenue +17.9%, EPS +144.6%, free cash flow +94.1% with operating margin 6.1% and ROIC 22.3%. Valuation already assumes a fairly strong business story at P/E 47.4 and price/sales 1.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines GRDN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
GRDN is 76.09 pts ahead over the shared 1Y window.
GRDN had 13.61 pts deeper max drawdown than SPY.
GRDN beat SPY in 2 of 2 calendar years shown and trailed in 0.
GRDN
+96.57%
Normalized return
SPY
+20.48%
S&P 500
Excess Return
+76.09 pts
Relative to SPY
GRDN Max Drawdown
-22.74%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for GRDN and SPY.
| Year | GRDN | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | +41.86% | +6.71% | +35.15 pts | GRDN |
| 2025 | +42.00% | +11.19% | +30.81 pts | GRDN |
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$792.1M
-12.9% YoY
FY Net Income
$16.3M
-53.9% YoY
Free Cash Flow
$49.2M
+55.0% YoY
Revenue Growth
+17.9%
EPS Growth
+144.6%
Gross Margin
19.5%
Net Margin
3.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.4B | 1.2B | 1.0B | 909M | 792M |
| Gross Profit | 282M | 244M | 208M | 186M | 161M |
| Operating Income | 89M | -63M | 41M | 52M | 30M |
| EBITDA | 111M | -43M | 59M | 68M | 46M |
| Net Income | 49M | -87M | 24M | 35M | 16M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 66M | 5M | 752K | 607K | 15M |
| Total Assets | 413M | 321M | 271M | 256M | 236M |
| Total Liabilities | 195M | 171M | 211M | 180M | 183M |
| Shareholder Equity | 206M | 143M | 28M | 43M | 24M |
| Total Debt | 45M | 37M | 69M | 63M | 55M |
| Net Debt | -21M | 33M | 68M | 62M | 40M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
58M
+20.6% YoY
Capital Expenditures
9M
+44.7% YoY
Free Cash Flow
49M
+55.0% YoY
Key ratios
Gross Margin
19.5%
Operating Margin
6.1%
Net Margin
3.4%
ROE
27.5%
Debt / Equity
0.22x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.